The cancer that originates from breast tissue, either from the lining of the milk duct or from the lobules, is known as breast cancer. Mostly, women are affected by breast cancer, but men can also be diagnosed with breast cancer at times.
In vitro study we conducted in collaboration with the same cancer center was published this year in the International Journal of Oncology, entitled, “Cytotoxic effects of ultra-diluted remedies on breast cancer cells”. We studied four homeopathic remedies against two human breast adenocarcinoma cell lines (MCF-7 and MDA-MB-231) and a cell line derived from immortalized normal human mammary epithelial cells (HMLE).
The remedies exerted preferential cytotoxic effects against the two breast cancer cell lines, causing cell cycle delay/arrest and apoptosis. These effects were accompanied by altered expression of the cell cycle regulatory proteins, as well as induction of the apoptotic cascade in the treated cells. The findings demonstrate that Banerji protocol remedies preferentially induce growth arrest and cell death response in human breast carcinoma cells compared with cells derived from normal mammary epithelial cells. The degree of these cytotoxic effects vary between the two breast carcinoma cell types analyzed, which differ in their estrogen receptor status and the presence of the tumor suppressor protein p53.
The cell division arrest and cell death responses in the carcinoma cells are accompanied with discrete changes in the expression profiles of the genes which control cell division and cell death and these gene expression changes indicate the underlying mechanisms responsible for the cytotoxic effects induced by the Banerji protocol remedies. All four of these remedies are used in our clinic for treatment of breast tumors.
According to our data of the above mentioned 941 cases, in 19% of the cases, the malignant tumors completely regressed and 21% of the cases were static or improved after treatment. In this group the tumors gradually improved/regressed and then became static. This group also includes cases where the tumor did not regress but became static. In cases with static tumors, the follow up continued for at least two years and in some cases the follow ups have continued for 10 years.